- Home
- JVA vs SNTI Comparison
JVA vs SNTI Comparison
Compare JVA & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JVA
- SNTI
- Stock Information
- Founded
- JVA 1971
- SNTI 2016
- Country
- JVA United States
- SNTI United States
- Employees
- JVA N/A
- SNTI 48
- Industry
- JVA Packaged Foods
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- JVA Consumer Staples
- SNTI Health Care
- Exchange
- JVA Nasdaq
- SNTI Nasdaq
- Market Cap
- JVA N/A
- SNTI 18.2M
- IPO Year
- JVA 2005
- SNTI N/A
- Fundamental
- Price
- JVA $3.68
- SNTI $3.97
- Analyst Decision
- JVA
- SNTI Strong Buy
- Analyst Count
- JVA 0
- SNTI 1
- Target Price
- JVA N/A
- SNTI $12.00
- AVG Volume (30 Days)
- JVA 162.6K
- SNTI 7.2M
- Earning Date
- JVA 02-07-2025
- SNTI 11-14-2024
- Dividend Yield
- JVA N/A
- SNTI N/A
- EPS Growth
- JVA N/A
- SNTI N/A
- EPS
- JVA 0.20
- SNTI N/A
- Revenue
- JVA $76,111,698.00
- SNTI N/A
- Revenue This Year
- JVA N/A
- SNTI $254.47
- Revenue Next Year
- JVA N/A
- SNTI $169.66
- P/E Ratio
- JVA $18.10
- SNTI N/A
- Revenue Growth
- JVA 17.27
- SNTI N/A
- 52 Week Low
- JVA $0.81
- SNTI $1.52
- 52 Week High
- JVA $4.66
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- JVA 47.99
- SNTI 47.37
- Support Level
- JVA $3.92
- SNTI $3.60
- Resistance Level
- JVA $4.66
- SNTI $5.96
- Average True Range (ATR)
- JVA 0.40
- SNTI 1.02
- MACD
- JVA -0.07
- SNTI -0.29
- Stochastic Oscillator
- JVA 22.22
- SNTI 5.74
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.